Akihiro Miya Selected Research

Thyroglobulin

12/2021	Long-term outcomes of cytologically benign thyroid tumors: a retrospective analysis of 3,102 patients at a single institution.
3/2021	Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate.
4/2018	Thyroid sclerosing mucoepidermoid carcinoma with eosinophilia distinct from the salivary type.
1/2018	Spontaneous Slowing and Regressing of Tumor Growth in Childhood/Adolescent Papillary Thyroid Carcinomas Suggested by the Postoperative Thyroglobulin-Doubling Time.
11/2016	Diagnosis and surgical indications of oxyphilic follicular tumors in Japan: Surgical specimens and cytology.
1/2016	Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves' disease.
5/2014	Papillary thyroid microcarcinoma might progress during pregnancy.
1/2014	Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy.
1/2014	Static and dynamic prognostic factors of papillary thyroid carcinoma.
6/2013	Evaluation of cytologically benign solitary thyroid nodules by ultrasonography: a retrospective analysis of 1877 cases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Akihiro Miya Research Topics

Disease

39	Neoplasms (Cancer) 07/2022 - 01/2004
38	Thyroid Neoplasms (Thyroid Cancer) 07/2022 - 01/2003
37	Carcinoma (Carcinomatosis) 12/2018 - 01/2003
28	Papillary Thyroid Cancer 03/2022 - 01/2005
25	Neoplasm Metastasis (Metastasis) 03/2022 - 04/2003
23	Papillary Carcinoma 01/2012 - 01/2003
8	Follicular Adenocarcinoma 09/2022 - 06/2008
7	Adenoma (Adenomas) 07/2015 - 05/2003
6	Lymphatic Metastasis 01/2010 - 01/2003
5	Breast Neoplasms (Breast Cancer) 07/2017 - 01/2004
5	Graves Disease (Basedow Disease) 01/2016 - 10/2003
4	Medullary Carcinoma 01/2014 - 01/2005
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2012 - 01/2005
3	Anaplastic Thyroid Carcinoma 01/2010 - 09/2007
2	Parathyroid Neoplasms (Parathyroid Neoplasm) 06/2021 - 01/2011
2	Proteinuria 12/2018 - 09/2018
2	Disease Progression 01/2018 - 11/2003
2	Thyroid Diseases (Thyroid Disease) 01/2017 - 07/2016
2	Hyperthyroidism 01/2017 - 01/2016
2	Wounds and Injuries (Trauma) 10/2015 - 11/2011
2	Hypoparathyroidism 01/2014 - 12/2013
2	Hypothyroidism 01/2014 - 01/2011
1	Fistula 08/2021
1	Hypertension (High Blood Pressure) 09/2018
1	Thrombotic Microangiopathies 09/2018
1	Graves Ophthalmopathy 01/2016
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 01/2014
1	Plasmacytoma 01/2014
1	Postmenopausal Osteoporosis 12/2013
1	Thyroid Nodule (Nodule, Thyroid) 03/2011
1	Goiter 01/2009
1	Hyperparathyroidism 01/2009
1	Primary Hyperparathyroidism 01/2009
1	Thyrotoxicosis 06/2008
1	Surgical Wound 11/2007

Drug/Important Bio-Agent (IBA)

19	Thyroglobulin FDA Link 12/2021 - 11/2004
15	Biological ProductsIBA 01/2012 - 01/2003
12	Proteins (Proteins, Gene)FDA Link 10/2009 - 01/2003
9	IodineIBA 03/2021 - 04/2005
8	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2020 - 01/2014
7	RacivirIBA 09/2022 - 01/2013
5	lenvatinibIBA 03/2021 - 09/2018
4	Phosphotransferases (Kinase)IBA 03/2021 - 09/2018
4	Indicators and Reagents (Reagents)IBA 01/2014 - 01/2005
4	Messenger RNA (mRNA)IBA 07/2009 - 01/2003
3	Capsules (Microcapsules)IBA 06/2021 - 01/2003
3	Sorafenib (BAY 43-9006)FDA Link 03/2021 - 09/2018
3	CalciumIBA 02/2018 - 03/2006
3	Estrogen ReceptorsIBA 07/2017 - 05/2014
3	Thyrotropin (Thyroid-Stimulating Hormone)FDA Link 05/2014 - 01/2011
3	Monoclonal AntibodiesIBA 01/2005 - 01/2003
2	Uridine Monophosphate (UMP)IBA 07/2022 - 07/2015
2	Biomarkers (Surrogate Marker)IBA 03/2022 - 01/2017
2	Carcinoembryonic AntigenIBA 12/2018 - 01/2014
2	Tumor Biomarkers (Tumor Markers)IBA 02/2018 - 07/2016
2	Dihydrotachysterol (AT 10)IBA 01/2018 - 01/2010
2	Anastrozole (Arimidex)FDA LinkGeneric 07/2017 - 04/2016
2	thyrotropin-binding inhibitory immunoglobulinIBA 01/2016 - 10/2003
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2012 - 01/2010
2	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2007 - 01/2005
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2005 - 01/2004
2	Carrier Proteins (Binding Protein)IBA 06/2005 - 07/2003
2	Calcium-Binding ProteinsIBA 01/2005 - 01/2004
1	AntigensIBA 03/2022
1	CarbohydratesIBA 03/2022
1	BariumIBA 08/2021
1	HemosiderinIBA 06/2021
1	SuspensionsIBA 12/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2018
1	Keratins (Keratin)IBA 04/2018
1	Tyrosine Kinase InhibitorsIBA 07/2016
1	Long-Acting Thyroid Stimulator (LATS)IBA 01/2016
1	Amyloid (Amyloid Fibrils)IBA 01/2014
1	Amyloidogenic ProteinsIBA 01/2014
1	Hormones (Hormone)IBA 01/2011
1	Differentiation AntigensIBA 07/2009
1	NestinIBA 07/2009
1	IodidesIBA 01/2009
1	3-FT (3 FT)IBA 06/2008
1	Iodide Peroxidase (Deiodinase)IBA 06/2008
1	Thyroxine (Levothyroxine)FDA LinkGeneric 06/2008
1	Thyroid Nuclear Factor 1IBA 09/2007
1	oncofetal fibronectinIBA 09/2007
1	PlasminogenIBA 07/2007
1	AnnexinsIBA 07/2007
1	Annexin A2 (Annexin II)IBA 07/2007

Therapy/Procedure

30	Thyroidectomy 03/2022 - 10/2003
13	Therapeutics 03/2021 - 04/2005
12	Neck Dissection (Radical Neck Dissection) 09/2020 - 01/2004
7	Lymph Node Excision (Lymph Node Dissection) 12/2011 - 04/2003
2	Operative Surgical Procedures 03/2012 - 01/2010
1	Cautery 08/2021
1	Aftercare (After-Treatment) 08/2021
1	Lasers (Laser) 08/2021
1	Drug Tapering 09/2018
1	Autologous Transplantation 01/2014
1	Drug Therapy (Chemotherapy) 01/2012
1	Parathyroidectomy 01/2011
1	Induction Chemotherapy 01/2010
1	Sutures (Suture) 11/2007